関連する実験動画
Updated: Aug 12, 2026
10:37
Ferric Chloride-induced Murine Thrombosis Models
Published on: September 5, 2016
血小板グリコプロテインIIIaのポリモルフィズムと冠動脈ステント血栓形成のリスク
D H Walter1, V Schächinger, M Elsner
1Department of Internal Medicine IV, University of Frankfurt, Germany.
Lancet (London, England)
|July 4, 1998
まとめ
PIA2遺伝子変異は,冠動脈ステント血栓形成のリスクを高めます. この発見は,パーソナライズされた抗血小板治療が,この遺伝子マーカーを有する患者にとって有益である可能性があることを示唆しています.
科学分野:
- 心血管医学は,心臓血管医学である.
- 遺伝学 遺伝学とは
- トロンボシス研究研究
背景:
- 冠動脈ステントは冠動脈狭窄症を効果的に治療しますが,ステント血栓形成のリスクがあります.
- 血小板の蓄積は,ステントの血栓形成の重要な要因です.
- この研究では,特定の血小板グリコプロテインIIIa遺伝子ポリモルフィズム (PIA2) と冠動脈ステント血栓形成のリスクとの関連を調査しています.
研究 の 目的:
- 血小板グリコプロテインIIIa遺伝子のPIA2アレルが冠動脈ステント血栓形成のリスクの増加と関連しているかどうかを判断する.
- 冠動脈ステントを挿入する患者のステント栓塞の遺伝的予測要因を特定する.
主な方法:
- 予見性研究では,冠動脈ステント挿入後の30日間,318人の患者を追跡した.
- ポリメラーゼ連鎖反応 (PCR) とゲル電泳法を使用して,PIA1およびPIA2アレルを特定しました.
- ロジスティック回帰分析では,ステント閉塞の確率比を計算し,PIA2アレルに関連する相対リスクを評価しました.
主要な成果:
- PIA2アレルは患者の19.8%に存在し,80.2%がPIA1.1に対して同位体であった.
- ステント血管閉塞は,PIA2アレルを持つ患者の9.5%で,PIA1同位体の患者の1.9%で発生しました.
- 多変量分析により,PIA1/A2遺伝子型がステント栓塞の唯一の有意な独立した予測因子 (オッズ比5.26) として特定されました.
結論:
- PIA2アレルを持つ患者は,冠動脈ステントの血栓形成のリスクが著しく高まります.
- この遺伝的傾向は,抗血小板治療のグリコプロテインIIb/IIIa阻害剤の使用を導く可能性があります.
- グリコプロテインIIb/IIIa阻害剤による潜在的に増加した出血合併症を考慮する必要があります.
関連する概念動画
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:22Formation of the Platelet Plug
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:26Coronary Artery Disease II: Pathophysiology
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
01:27Peripheral Artery Disease III: Interprofessional Care
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...